Application of principal component analysis to pharmacogenomic studies in Canada
about
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.Applying genome-wide gene-based expression quantitative trait locus mapping to study population ancestry and pharmacogeneticsA coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.Methods to analyze big data in pharmacogenomics research.HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations.Development of a broad-based ADME panel for use in pharmacogenomic studies.Human loci involved in drug biotransformation: worldwide genetic variation, population structure, and pharmacogenetic implications.An epigenome-wide association study of inflammatory response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America.Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.Genetic markers of cisplatin-induced hearing loss in children.Genetic variants inSLC22A17 and SLC22A7are associated with anthracycline-induced cardiotoxicity in children
P2860
Q33553382-52496628-14B8-41F8-A757-B735E997D374Q34539515-FF959B93-EC3D-465E-BE0B-F13A629BB2D1Q36004460-1ECE33C7-730D-444A-8AF0-763EA8CFA5F2Q36404935-9E8C288D-C06A-40C3-9125-C35A389B40FEQ37341208-8A50B894-D0A9-488C-80A4-EC2450D68B62Q37809965-7C719021-9010-4124-80AE-1B93DCB1E855Q39142325-8DED44C7-36CD-4330-B692-F229F98CAFABQ39203656-E727C973-755E-49C3-A367-86FF82B9479AQ40073257-F31CF0B2-BC1C-4E4F-AF44-93364D83EA1BQ40414168-C25D7076-6992-4A4B-AB66-163E9283C84DQ46409053-7E0EB68C-BA73-4909-8A74-C28FDA329DCAQ50354505-98C15850-968B-4635-882B-DA008F103008Q58862883-B1DEA3F4-68EB-43CB-9BE3-F70A0A16032D
P2860
Application of principal component analysis to pharmacogenomic studies in Canada
description
article
@en
im August 2009 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2009
@uk
name
Application of principal component analysis to pharmacogenomic studies in Canada
@en
Application of principal component analysis to pharmacogenomic studies in Canada
@nl
type
label
Application of principal component analysis to pharmacogenomic studies in Canada
@en
Application of principal component analysis to pharmacogenomic studies in Canada
@nl
prefLabel
Application of principal component analysis to pharmacogenomic studies in Canada
@en
Application of principal component analysis to pharmacogenomic studies in Canada
@nl
P2093
P2860
P50
P356
P1476
Application of principal component analysis to pharmacogenomic studies in Canada
@en
P2093
A M K Brown
H Visscher
M S Phillips
P2860
P2888
P304
P356
10.1038/TPJ.2009.36
P577
2009-08-04T00:00:00Z